Renal Cell Carcinoma

Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading

Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading

By

A review article examines the challenges in pathologic staging and grade reporting for patients with renal cell carcinoma.

Karyopherin a2 May Be Prognostic Indicator in Renal Cell Carcinoma

Karyopherin a2 May Be Prognostic Indicator in Renal Cell Carcinoma

By

Researchers theorize that KPNA2 expression could be used in the future to stratify risk groups among patients with renal cell carcinoma (RCC).

The Changing Treatment Landscape for Advanced Renal Cell Carcinoma

The Changing Treatment Landscape for Advanced Renal Cell Carcinoma

By

Interferon or high-dose interleukin-2 were the only available options for the treatment of metastatic RCC until 2005.

VEGF-TKI Adjuvant Trial Results in Renal Cell Carcinoma Highlight Controversy in Treatment Strategy

VEGF-TKI Adjuvant Trial Results in Renal Cell Carcinoma Highlight Controversy in Treatment Strategy

By

Insights into controversial results of trials evaluating adjuvant vascular endothelial growth factor tyrosine kinase inhibitors in high-risk renal cell carcinoma.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Microwave Ablation for Early-Stage Renal Tumors

Microwave Ablation for Early-Stage Renal Tumors

By

Image-guided microwave ablation of early-stage renal tumors shows promise but a new retrospective study from the Mayo Clinic found some cases of major bleeding.

High Distress in Patients With Renal Cell Carcinoma, Call for Better Psychosocial Screening

High Distress in Patients With Renal Cell Carcinoma, Call for Better Psychosocial Screening

By

A high prevalence of patients with renal cell carcinoma reported distress, highlighting the need for better psychosocial screening of patients.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Cabozantinib Effective Regardless of PD-L1 Expression in RCC

Cabozantinib Effective Regardless of PD-L1 Expression in RCC

By

PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks

Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks

By

A flat-dosing schedule of nivolumab (480 mg every 4 weeks) showed pharmacologic activity and safety similar to other schedules.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

By

Long-term oncologic outcomes of patients with sporadic RCC who underwent robotic tumor enucleation suggest the procedure is safe.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Drug Targeting ENPP3 Is Active in Heavily Pretreated, Advanced Metastatic RCC

Drug Targeting ENPP3 Is Active in Heavily Pretreated, Advanced Metastatic RCC

By

An antibody-drug conjugate targeting ectonucleotide pyrophosphatase/phosphodiesterase 3 conjugated to monomethyl auristatin F had some antitumor activity in patients with advanced, metastatic renal cell carcinoma.

The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

By

Researchers found that doubling in KIM-1 plasma concentrations was associated with an increased risk of developing RCC and poorer survival.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

By

When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC

By

Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes

By

The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.

Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

By

A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.

Clues from DNA Repair Mechanisms Could Drive Novel Therapeutic Strategies

Clues from DNA Repair Mechanisms Could Drive Novel Therapeutic Strategies

By

Metabolites from the Krebs cycle were found to suppress the DNA-repair pathway required for the preservation of genomic integrity.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Nonsurgical treatment of small tumor renal cancer may be as effective as radical nephrectomy but with fewer complications

Renal stage carcinoma (RCC) has relatively low mortality rates with respect to cancer diagnoses, as the disease tends to be slow growing.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma

By

Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs